Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
La radiologia medica
Erschienen in:

01.06.2019 | VASCULAR AND INTERVENTIONAL RADIOLOGY

Safety of transarterial radioembolization with Yttrium-90 glass microspheres without cystic artery occlusion

verfasst von: Osman Melih Topcuoglu, Nalan Alan Selcuk, Basar Sarikaya, Turkay Toklu

Erschienen in: La radiologia medica | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess radiation-induced cholecystitis in cases of cystic artery origin nearby the treatment zone for transarterial radioembolization (TARE) treatment.

Materials and methods

Patients with primary or secondary malignant liver tumors treated with TARE, in whom cystic artery was located in the surrounding area of the treatment zone on 99m-technetium-MAA angiograms, were included in this study. Whole liver dose, tumor dose and healthy injected liver dose, lung dose and if applicable the gallbladder dose were all calculated by using the Medical Internal Radiation Dose (MIRD) formula from SPECT–CT images. Qualitative and quantitative assessment of the gallbladder was performed on SPECT–CT. The observed adverse events were classified according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE v5.0).

Results

A total of 34 TARE procedures from 29 patients (18 men and 11 women), with a mean age of 65 ± 13.3 years meeting the inclusion criteria, were involved in the current study. The mean tumor dose, healthy injected liver dose, healthy whole liver dose and gallbladder dose were 204.9 ± 66.8 Gy, 70.5 ± 15.7 Gy, 31.1 ± 12.7 Gy and 96.4 ± 53.4 Gy, respectively. The mean follow-up period was 14 ± 5.2 months. Qualitative assessment revealed gallbladder radioactivity on SPECT–CT in 11 (32.3%) patients with six mild and five moderate–severe radioactivities. There were no detected grade 2 or 3 adverse events.

Conclusion

TARE is safely performed without cystic artery embolization when its origin is close to the treatment area.
Literatur
1.
Jakobs TF, Hoffmann RT, Dehm K, Trumm C, Stemmler HJ, Tatsch K et al (2008) Hepatic Yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol 19:1187–1195CrossRefPubMed
2.
3.
Murthy R, Xiong H, Nunez R, Cohen AC, Barron B, Szklaruk J et al (2005) Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol 16:937–945CrossRefPubMed
4.
Lewandowski RJ, Salem R (2006) Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol 23:64–72CrossRefPubMedPubMedCentral
5.
Borggreve AS, Landman A, Vissers CMJ, De Jong CD, Lam M, Monninkhof EM et al (2016) Radioembolization: is prophylactic embolization of hepaticoenteric arteries necessary? A systematic review. Cardiovasc Interv Radiol 39:696–704CrossRef
6.
Riaz A, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK et al (2009) Complications following radioembolization with Yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 20:1121–1130 (quiz 31) CrossRefPubMed
7.
Peterson JL, Vallow LA, Johnson DW, Heckman MG, Diehl NN, Smith AA et al (2013) Complications after 90Y microsphere radioembolization for unresectable hepatic tumors: an evaluation of 112 patients. Brachytherapy 12:573–579CrossRefPubMed
8.
Atassi B, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, Mulcahy MF et al (2008) Biliary sequelae following radioembolization with Yttrium-90 microspheres. J Vasc Interv Radiol 19:691–697CrossRefPubMed
9.
Lauenstein TC, Heusner TA, Hamami M, Ertle J, Schlaak JF, Gerken G et al (2011) Radioembolization of hepatic tumors: flow redistribution after the occlusion of intrahepatic arteries. Rofo 183:1058–1064CrossRefPubMed
10.
Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek AA Jr, Kulik L et al (2007) Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Interv Radiol 30:571–592CrossRef
11.
Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C et al (2010) The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med 51:1206–1212CrossRefPubMed
12.
Lenoir L, Edeline J, Rolland Y, Pracht M, Raoul JL, Ardisson V et al (2012) Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization. Eur J Nucl Med Mol Imaging 39:872–880CrossRefPubMedPubMedCentral
13.
Hamami ME, Poeppel TD, Muller S, Heusner T, Bockisch A, Hilgard P et al (2009) SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer. J Nucl Med 50:688–692CrossRefPubMed
14.
Schelhorn J, Theysohn J, Ertle J, Schlaak JF, Mueller S, Bockisch A et al (2014) Selective internal radiation therapy of hepatic tumours: is coiling of the gastroduodenal artery always beneficial? Clin Radiol 69:e216–e222CrossRefPubMed
15.
Petroziello MF, McCann JW, Gonsalves CF, Eschelman DJ, Anne PR, Sato T et al (2011) Side-branch embolization before 90Y radioembolization: rate of recanalization and new collateral development. AJR Am J Roentgenol 197:W169–W174CrossRefPubMed
16.
Abdelmaksoud MH, Hwang GL, Louie JD, Kothary N, Hofmann LV, Kuo WT et al (2010) Development of new hepaticoenteric collateral pathways after hepatic arterial skeletonization in preparation for Yttrium-90 radioembolization. J Vasc Interv Radiol 21:1385–1395CrossRefPubMed
17.
Hamoui N, Minocha J, Memon K, Sato K, Ryu R, Salem R et al (2013) Prophylactic embolization of the gastroduodenal and right gastric arteries is not routinely necessary before radioembolization with glass microspheres. J Vasc Interv Radiol 24:1743–1745CrossRefPubMed
18.
Theysohn JM, Muller S, Schlaak JF, Ertle J, Schlosser TW, Bockisch A et al (2013) Selective internal radiotherapy (SIRT) of hepatic tumors: how to deal with the cystic artery. Cardiovasc Interv Radiol 36:1015–1022CrossRef
19.
Boas FE, Bodei L, Sofocleous CT (2017) Radioembolization of colorectal liver metastases: indications, technique, and outcomes. J Nucl Med 58:104S–111SCrossRefPubMed
20.
21.
Molmenti EP, Pinto PA, Klein J, Klein AS (2003) Normal and variant arterial supply of the liver and gallbladder. Pediatr Transpl 7:80–82CrossRef
22.
Mlakar B, Gadzijev EM, Ravnik D, Hribernik M (2003) Anatomical variations of the cystic artery. Eur J Morphol 41:31–34CrossRefPubMed
23.
Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J et al (2006) Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 66:792–800CrossRefPubMed
24.
Garin E, Rolland Y, Boucher E, Ardisson V, Laffont S, Boudjema K et al (2010) First experience of hepatic radioembolization using microspheres labelled with Yttrium-90 (TheraSphere): practical aspects concerning its implementation. Eur J Nucl Med Mol Imaging 37:453–461CrossRefPubMed
25.
Padia SA, Lewandowski RJ, Johnson GE, Sze DY, Ward TJ, Gaba RC et al (2017) Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions. J Vasc Interv Radiol 28:1–15CrossRefPubMed
26.
Powerski M, Busse A, Seidensticker M, Fischbach F, Seidensticker R, Strach K et al (2015) Prophylactic embolization of the cystic artery prior to radioembolization of liver malignancies—an evaluation of necessity. Cardiovasc Interv Radiol 38:678–684CrossRef
27.
McWilliams JP, Kee ST, Loh CT, Lee EW, Liu DM (2011) Prophylactic embolization of the cystic artery before radioembolization: feasibility, safety, and outcomes. Cardiovasc Interv Radiol 34:786–792CrossRef
28.
Prince JF, van den Hoven AF, van den Bosch MA, Elschot M, de Jong HW, Lam MG (2014) Radiation-induced cholecystitis after hepatic radioembolization: do we need to take precautionary measures? J Vasc Interv Radiol 25:1717–1723CrossRefPubMed
29.
Kao YH, Hock Tan AE, Burgmans MC, Irani FG, Khoo LS, Gong Lo RH et al (2012) Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization. J Nucl Med 53:559–566CrossRefPubMed
30.
van den Hoven AF, Prince JF, Samim M, Arepally A, Zonnenberg BA, Lam MG et al (2014) Posttreatment PET-CT-confirmed intrahepatic radioembolization performed without coil embolization, by using the antireflux surefire infusion system. Cardiovasc Interv Radiol 37:523–528CrossRef
31.
Salem R, Thurston KG (2006) Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol 17:1251–1278CrossRefPubMed
32.
Parakh S, Gananadha S, Allen R, Yip D (2016) Cholecystitis after Yttrium-90 resin microsphere radioembolization treatment: clinical and pathologic findings. Asian J Surg 39:144–148CrossRefPubMed
33.
Bester L, Meteling B, Pocock N, Pavlakis N, Chua TC, Saxena A et al (2012) Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol 23:96–105CrossRefPubMed
Metadaten
Titel
Safety of transarterial radioembolization with Yttrium-90 glass microspheres without cystic artery occlusion
verfasst von
Osman Melih Topcuoglu
Nalan Alan Selcuk
Basar Sarikaya
Turkay Toklu
Publikationsdatum
01.06.2019
Verlag
Springer Milan
Erschienen in
La radiologia medica / Ausgabe 6/2019
Print ISSN: 0033-8362
Elektronische ISSN: 1826-6983
DOI
https://doi.org/10.1007/s11547-018-00984-9

Weitere Artikel der Ausgabe 6/2019

Diagnostic accuracy of dual-energy CT and virtual non-calcium techniques to evaluate bone marrow edema in vertebral compression fractures

  • COMPUTED TOMOGRAPHY

Misleading findings of liver-specific MR contrast agent for radiological diagnosis of cysto-biliary communication in hydatid cysts

  • ABDOMINAL RADIOLOGY

Machine learning-based radiomic models to predict intensity-modulated radiation therapy response, Gleason score and stage in prostate cancer

  • ONCOLOGY IMAGING

There are more anatomical variants in heaven and earth, Horatio, than are dreamt of in our philosophy: the precaval left renal artery

  • ABDOMINAL RADIOLOGY

Hybrid volumetric modulated arc therapy for whole breast irradiation: a dosimetric comparison of different arc designs

  • MEDICAL PHYSICS

Position paper on magnetic resonance imaging protocols in the musculoskeletal system (excluding the spine) by the Italian College of Musculoskeletal Radiology

  • MAGNETIC RESONANCE IMAGING

Neu im Fachgebiet Radiologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Stumme Schlaganfälle − ein häufiger Nebenbefund im Kopf-CT?

In 4% der in der Notfallambulanz initiierten zerebralen Bildgebung sind „alte“ Schlaganfälle zu erkennen. Gar nicht so selten handelt es sich laut einer aktuellen Studie dabei um unbemerkte Insulte. Bietet sich hier womöglich die Chance auf ein effektives opportunistisches Screening?

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Stören weiße Wände und viel Licht die Bildqualitätskontrolle?

Wenn es darum geht, die technische Qualität eines Mammogramms zu beurteilen, könnten graue Wandfarbe und reduzierte Beleuchtung im Bildgebungsraum von Vorteil sein. Darauf deuten zumindest Ergebnisse einer kleinen Studie hin. 

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise